TOP TEN perturbations for 1553147_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553147_at
Selected probe(set): 1553147_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553147_at (1553147_at) across 6672 perturbations tested by GENEVESTIGATOR:

E. coli study 1 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):4.8540096
Number of Samples:12 / 16
Experimental E. coli study 1
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):4.757126
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):4.3205233
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):4.2398744
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):4.192425
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

HCC study 26 (tumor; TG/GG genotype) / HCC study 26 (non-tumor; TG/GG genotype)

Relative Expression (log2-ratio):-2.2218542
Number of Samples:10 / 10
Experimental HCC study 26 (tumor; TG/GG genotype)
Liver tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).
Control HCC study 26 (non-tumor; TG/GG genotype)
Liver non-tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).

osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / osteoarthritis study 46 (TNF; IL-17; baseline)

Relative Expression (log2-ratio):-1.9503684
Number of Samples:6 / 6
Experimental osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with osteoarthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control osteoarthritis study 46 (TNF; IL-17; baseline)
Joint synovial fibroblast samples at baseline from patients with osteoarthritis before treatment with 1ng/ml TNF and/or IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

dendritic cell study 6 (CpG A) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):1.7837248
Number of Samples:7 / 8
Experimental dendritic cell study 6 (CpG A)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / osteoarthritis study 46 (untreated)

Relative Expression (log2-ratio):-1.655107
Number of Samples:6 / 6
Experimental osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with osteoarthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control osteoarthritis study 46 (untreated)
Joint synovial fibroblast samples from patients with osteoarthritis. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; chest wall)

Relative Expression (log2-ratio):-1.5874205
Number of Samples:7 / 2
Experimental breast cancer study 42 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; chest wall)
Metastatic tumor tissue obtained from the chest wall of patients with primary breast adenocarcinoma.